| 2.16 -0.17 (-7.3%) | 05-15 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 2.83  |
1-year : | 3.03 |
| Resists | First : | 2.42 |
Second : | 2.59 |
| Pivot price | 2.35 |
|||
| Supports | First : | 2.14 |
Second : | 1.78 |
| MAs | MA(5) : | 2.34 |
MA(20) : | 2.35 |
| MA(100) : | 2.28  |
MA(250) : | 1.46 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 33.6 |
D(3) : | 53.2 |
| RSI | RSI(14): 39.5 |
|||
| 52-week | High : | 3.61 | Low : | 0.49 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ CNTX ] has closed below the lower bollinger band by 10.8%. If price is in a downtrend band; this downward trend might continue. However a short term pullback inside the band is likely. Bollinger Bands are 53.4% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 12 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 2.3 - 2.32 | 2.32 - 2.33 |
| Low: | 2.11 - 2.13 | 2.13 - 2.14 |
| Close: | 2.14 - 2.16 | 2.16 - 2.18 |
Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of cancer for women in the United States. Its lead product candidate is onapristone extended release (ONA-XR), a potent and selective antagonist of the progesterone receptor that is linked to resistance for various classes of cancer therapeutics, such as anti-estrogen therapies across female hormone-dependent cancers. The company is also developing CLDN6xCD3 bsAb, an anti-CD3 x anti-Claudin 6 antigen bispecific monoclonal antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of an anti-claudin 6 bispecific monoclonal antibody for gynaecologic cancer therapy. Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.
Fri, 15 May 2026
Context Therapeutics (CNTX) joint filing shows 2.44% ownership by Great Point Partners - Stock Titan
Thu, 14 May 2026
Blue Owl Capital Holdings (CNTX) Discloses 5.54% Ownership in Context Therapeutics - Stock Titan
Thu, 14 May 2026
Octagon, Master Fund, Ting Jia file 5.25M-share holding in CNTX (5.7%) - Stock Titan
Tue, 12 May 2026
Avidity entities hold 8.7% of Context Therapeutics (NASDAQ: CNTX) - Stock Titan
Wed, 06 May 2026
Context Therapeutics Reports First Quarter 2026 Operating and Financial Results - ChartMill
Wed, 06 May 2026
Context Therapeutics Reports First Quarter 2026 Operating and Financial Results - Sahm
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 92 (M) |
| Shares Float | 43 (M) |
| Held by Insiders | 1.1 (%) |
| Held by Institutions | 76.8 (%) |
| Shares Short | 864 (K) |
| Shares Short P.Month | 1,290 (K) |
| EPS | -0.38 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.66 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -29.8 % |
| Return on Equity (ttm) | -46.4 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.44 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -26 (M) |
| Levered Free Cash Flow | -19 (M) |
| PE Ratio | -5.69 |
| PEG Ratio | 0 |
| Price to Book value | 3.27 |
| Price to Sales | 0 |
| Price to Cash Flow | -7.53 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|